The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology - A Case-Control Study.
aging
breast neoplasms
menopause
muscles
obesity
sarcopenia
Journal
Journal of multidisciplinary healthcare
ISSN: 1178-2390
Titre abrégé: J Multidiscip Healthc
Pays: New Zealand
ID NLM: 101512691
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
08
2020
accepted:
22
09
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
8
12
2020
Statut:
epublish
Résumé
Sarcopenic obesity (SO) is characterized as the cooccurrence of sarcopenia and obesity. It is associated with many adverse health consequences, also in oncological patients. The study aimed to assess the prevalence of SO in postmenopausal women with a history of breast cancer depending on adopted methodology. The case-control study enrolled 103 women over the age of 50 with a history of breast cancer, including women who completed oncological treatment and had remained in remission for at least 5 years (group I, n=78) and women in whom the disease recurred (group II, n=25). The control group included women with no history of breast cancer (group III, n=73). In group II sarcopenia occurred significantly more commonly compared to both group I and the control group (for the skeletal muscle index (SMI) ≤29.20%: 13 (52%) in group II vs 16 (20.5%) in group I, p=0.004 and 3 (4.1%) in group III, p<0.001; for SMI ≤26.60%: 10 (40%) in group II vs 9 (11.5%) in group I, p=0.003 and 3 (4.1%) in group III, p<0.001; for SMI ≤33.87%: 17 (68%) in group II vs 21 (26.9%) in group I, p<0.001 and 5 (6.8%) in group III, p<0.001). Depending on the assessment criteria, SO was diagnosed in 0-11.5% of cases in group I, 0-40% of cases in group II and 0-4.1% in the control group. Intergroup differences were not statistically significant, irrespective of the adopted pair of diagnostic criteria. The highest detectability of SO was observed when SMI was combined with each of the diagnostic criteria for obesity used. SO diagnosis based on the percentage of fatty tissue mass in the body of >38% and SMI value were associated with a higher detection rate of SO in each study group, regardless of the adopted cut-off value. Similar results were obtained in each analyzed group when using the remaining diagnostic criteria for obesity and SMI value, regardless of the cut-off value.
Identifiants
pubmed: 33281453
doi: 10.2147/JMDH.S274660
pii: 274660
pmc: PMC7708830
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1749-1758Informations de copyright
© 2020 Kałędkiewicz et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Eur J Cancer. 2016 Oct;66:153-61
pubmed: 27573429
J Am Geriatr Soc. 2002 May;50(5):889-96
pubmed: 12028177
Clin Nutr ESPEN. 2016 Jun;13:e39-e45
pubmed: 28531567
Support Care Cancer. 2018 Mar;26(3):861-868
pubmed: 28948392
Am J Clin Nutr. 2013 Oct;98(4):1012-9
pubmed: 23966429
Nutrition. 2016 Nov-Dec;32(11-12):1231-7
pubmed: 27261062
Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9
pubmed: 29506228
Nat Rev Clin Oncol. 2013 Feb;10(2):90-9
pubmed: 23207794
Annu Rev Nutr. 2018 Aug 21;38:357-379
pubmed: 29727593
Br J Cancer. 2012 Sep 4;107(6):931-6
pubmed: 22871883
Br J Surg. 2016 Mar;103(4):434-42
pubmed: 26780231
Clin Exerc Physiol. 2002 Feb;4(1):44-49
pubmed: 16946801
JAMA Oncol. 2018 Jun 1;4(6):804-805
pubmed: 29621383
J Clin Oncol. 2001 May 1;19(9):2381-9
pubmed: 11331316
Clin Nutr. 2012 Feb;31(1):74-7
pubmed: 21875767
Oncologist. 2012;17(10):1240-5
pubmed: 22903527
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Curr Oncol Rep. 2016 Oct;18(10):62
pubmed: 27541923
J Gastrointest Surg. 2010 Nov;14(11):1832-7
pubmed: 20725799
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Pol Merkur Lekarski. 2015 Apr;38(226):206-10
pubmed: 25938387
World J Surg. 2011 Feb;35(2):415-23
pubmed: 21153815
Ann Oncol. 2010 Aug;21(8):1594-1598
pubmed: 20089558
Ann N Y Acad Sci. 2000 May;904:437-48
pubmed: 10865787
J Nutr Health Aging. 2008 Mar;12(3):202-6
pubmed: 18309443
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):388-95
pubmed: 18395429
Breast. 2017 Feb;31:9-15
pubmed: 27810702
Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):693-700
pubmed: 18827572
Am J Clin Nutr. 2009 Apr;89(4):1173-9
pubmed: 19244378
BMJ. 2017 Feb 28;356:j477
pubmed: 28246088
Clin Cancer Res. 2007 Jun 1;13(11):3264-8
pubmed: 17545532
Curr Oncol Rep. 2018 Apr 11;20(6):47
pubmed: 29644507
Ann Surg Oncol. 2008 Jul;15(7):1918-22
pubmed: 18392660
J Clin Oncol. 2014 Nov 1;32(31):3568-74
pubmed: 25273035
Clin Adv Hematol Oncol. 2016 Oct;14(10):790-797
pubmed: 27930630
Int J Obes Relat Metab Disord. 2002 Jul;26(7):953-60
pubmed: 12080449
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
Eur Radiol. 2014 May;24(5):998-1005
pubmed: 24535076
J Cancer Surviv. 2012 Dec;6(4):398-406
pubmed: 23054848
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Am J Clin Nutr. 2017 Jul;106(1):125-129
pubmed: 28539380
J Natl Cancer Inst. 2015 Sep 30;107(12):djv275
pubmed: 26424778
Clin Cancer Res. 2009 Nov 15;15(22):6973-9
pubmed: 19887488